Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Natural Products Journal, The
  4. Volume 15, Issue 3
  5. Article
Volume 15, Issue 3
  • ISSN: 2210-3155
  • E-ISSN: 2210-3163

Abstract

Background

The characterization of resistance-associated amino acid substitution (RAAS) in direct-acting antivirals (DAA) molecular targets could reshape the treatment strategy for HCV infection. Hence, this review aimed to provide evidence on the impact of the RAASs on DAA treatment for HCV.

Methods

PRISMA model was followed for the literature survey and evaluation (sources: PubMed, Sci-Hub, and Google Scholar). RAASs in DAA target proteins and their locations were mapped on 3-D proteins using two reference protein sequences: NS3/ID: AAA72945.1 and NS5A/NS5B/ID: NP_671491.1. NCBI-Basic Local Alignment Tool, UniProt and AlphaFold2/MMSeqs2, PyMol, and R-base/R-studio were used for alignment, retrieval of protein sequences, 3-D protein structure modeling, visualization of locations of RAASs, and diagrammatic representations, respectively.

Results

Genotype 4 afterwards genotype 1 was the most prevalent in Saudi Arabia. L2003M, Y2065N, M2000T, L2003V, and Q2002H RAASs were anti-NS5A inhibitor. NS5A-Q2002H was anti-daclatasvir in genotype 4. NS5A-Y2065H and NS5B-S2702T in genotype 1 were anti-sofosbuvir-resistant. NS3-A1182V, NS3-Q1106K/R, and NS3-T1080S RAASs exhibited resistance to double antivirals. NS3-D1194A RAAS was a multi-drug resistant variant (against 3 DAAs). NS3- V1062A, NS3-D1194G, NS3-D1194E/T, NS3- S1148R, NS3-V1196A, NS3-V1062LNS3-S1148A, and NS3-S1148G RAASs in genotype 1 were single drug-resistant variants. NS3- S1148R and NS3-S1148A in genotypes 2 and 5 were anti-simeprevir-resistant variants.

Conclusions

An array of identified RAASs, RAAS-dependent DAA treatment failure, and recommended combination DAA therapy in such clinical scenarios of RAASs are the significant outcomes of this research. RAAS-linked and resistance profiling at genotype/sub-genotype level will be crucial in treatment choice and for future DAA design strategies.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/npj/10.2174/0122103155291056240327033157
2024-04-03
2025-01-19

  • From This Site

    /content/journals/npj/10.2174/0122103155291056240327033157
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SaravananS. VeluV. KumarasamyN. NandakumarS. MurugavelK.G. BalakrishnanP. SunitiS. ThyagarajanS.P. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India.World J. Gastroenterol.200713375015502010.3748/wjg.v13.i37.5015 17854146
     [Google Scholar]
  2. MaugerD.M. GoldenM. YamaneD. WillifordS. LemonS.M. MartinD.P. WeeksK.M. Functionally conserved architecture of hepatitis C virus RNA genomes.Proc. Natl. Acad. Sci.2015112123692369710.1073/pnas.1416266112 25775547
     [Google Scholar]
  3. WedemeyerH. DoreG.J. WardJ.W. Estimates on HCV disease burden worldwide – filling the gaps.J. Viral Hepat.201522S11510.1111/jvh.12371 25560838
     [Google Scholar]
  4. AlterH.J. SeeffL.B. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome.Semin. Liver Dis.2000201173510.1055/s‑2000‑9505
     [Google Scholar]
  5. YounossiZ.M. TanakaA. EguchiY. LimY.S. YuM.L. KawadaN. DanY.Y. RooneyB.C. NegroF. MondelliM.U. The impact of hepatitis C virus outside the liver: Evidence from Asia.Liver Int.201737215917210.1111/liv.13272 27748564
     [Google Scholar]
  6. WilliamsR. Global challenges in liver disease.Hepatology200644352152610.1002/hep.21347 16941687
     [Google Scholar]
  7. MannsM.P. ButiM. GaneE. PawlotskyJ.M. RazaviH. TerraultN. YounossiZ. Hepatitis C virus infection.Nat. Rev. Dis. Primers2017311700610.1038/nrdp.2017.6 28252637
     [Google Scholar]
  8. CougotD. NeuveutC. BuendiaM.A. HBV induced carcinogenesis.J. Clin. Virol.200534S1S75S7810.1016/S1386‑6532(05)80014‑9 16461228
     [Google Scholar]
  9. KunaL. JakabJ. SmolicR. WuG.Y. SmolicM. HCV extrahepatic manifestations.J. Clin. Transl. Hepatol.201972172182 31293918
     [Google Scholar]
  10. AljumahA.A. AbaalkhailF. Al-AshgarH. AssiriA. BabatinM. Al FalehF. AlghamdiA. HakeemA.R. HashimA. AlqutubA. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.Saudi J. Gastroenterol.2016224269
     [Google Scholar]
  11. FarciP. New insights into the HCV quasispecies and compartmentalization.Semin. Liver Dis.201131435637410.1055/s‑0031‑1297925
     [Google Scholar]
  12. AndinoR. DomingoE. Viral quasispecies.Virology2015479-480465110.1016/j.virol.2015.03.022 25824477
     [Google Scholar]
  13. KeikhaM. EslamiM. YousefiB. HassanzadehA.M. KamaliA. YousefiM. KarbalaeiM. HCV genotypes and their determinative role in hepatitis C treatment.Virusdisease202031323524010.1007/s13337‑020‑00592‑0 32904762
     [Google Scholar]
  14. JamallI.S. YusufS. AzharM. JamallS. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?World J. Gastroenterol.200814436627663110.3748/wjg.14.6627 19034963
     [Google Scholar]
  15. DuaA. DesaiS.S. KumarN. HellerJ. Epidemiology and treatment strategies of iliac vein thrombophlebitis.Vascular201523659960110.1177/1708538114565693 25575974
     [Google Scholar]
  16. ZeinN.N. Clinical significance of hepatitis C virus genotypes.Clin. Microbiol. Rev.200013222323510.1128/CMR.13.2.223 10755999
     [Google Scholar]
  17. CaiL.N. ZhuS.W. ZhouC. WangY.B. JiangN.Z. ChenH. TangX.Y. WangJ.H. ChenX. HuW.J. ChenB.W. ChenB.A. Infection status of HBV, HCV and HIV in voluntary blood donors of Chinese Nanjing area during 2010-2013.J. Exp. Hematol.20142241089109310.7534/j.issn.1009‑2137.2014.04.038 25130834
     [Google Scholar]
  18. WileyT.E. BrownJ. ChanJ. Hepatitis C infection in African Americans: its natural history and histological progression.Am. J. Gastroenterol.200297370070610.1111/j.1572‑0241.2002.05555.x 11922566
     [Google Scholar]
  19. BawazirA. AlGusheriF. JradiH. AlBalwiM. Abdel-GaderA.G. Hepatitis C virus genotypes in Saudi Arabia: A future prediction and laboratory profile.Virol. J.201714120810.1186/s12985‑017‑0873‑7 29096662
     [Google Scholar]
  20. AzizH. RazaA. MurtazaS. WaheedY. KhalidA. IrfanJ. SamraZ. AtharM.A. Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis.Int. J. Infect. Dis.2013174e247e25310.1016/j.ijid.2012.09.017 23183233
     [Google Scholar]
  21. ZeinN.N. PersingD.H. Hepatitis C genotypes: Current trends and future implications.Mayo Clin. Proc.199671545846210.4065/71.5.458 8628025
     [Google Scholar]
  22. AbozaidS.M. ShoukriM. QahtaniA.A. AhdalA.M.N. Prevailing genotypes of hepatitis C virus in Saudi Arabia: A systematic analysis of evidence.Ann. Saudi Med.20133311510.5144/0256‑4947.2013.1 23458931
     [Google Scholar]
  23. AlmosaF.A.M. AlnasserA.H.A. Al-TawfiqJ.A. Distribution of hepatitis C virus (HCV) genotypes in a Saudi Arabian hospital during the 2015-2020 period.Infez. Med.202129345045510.53854/liim‑2903‑16 35146350
     [Google Scholar]
  24. WardS. LauerG. IsbaR. WalkerB. KlenermanP. Cellular immune responses against hepatitis C virus: The evidence base 2002.Clin. Exp. Immunol.2002128219520310.1046/j.1365‑2249.2002.01840.x 11985510
     [Google Scholar]
  25. LuJ. FengY. ChenL. ZengZ. LiuX. CaiW. WangH. GuoX. ZhouH. TaoW. XieQ. Subtype-specific prevalence of hepatitis C virus NS5A resistance associated substitutions in Mainland China.Front. Microbiol.20191053510.3389/fmicb.2019.00535 30941111
     [Google Scholar]
  26. DietzJ. MüllhauptB. BuggischP. GrafC. PeifferK.H. MatschenzK. SchattenbergJ.M. AntoniC. MaussS. NiederauC. DischerT. TrauthJ. DultzG. zur WieschS.J. PiechaF. KlinkerH. MüllerT. BergT. HaefelinN.C. BergC.P. ZeuzemS. SarrazinC. BalavoineJ. GiostraE. BerningM. HampeJ. CanbayA. SteckstorW. SchmiegelW. BrockmeyerN.H. De GottardiA. RauchA. SemmoN. FischerJ. GressM. HeinzowH. HilgardG. SchmidtH. HerrmannA. StallmachA. HoffmannD. ProtzerU. KlinkerH. SchulzeP. KodalA. KremerA. SieblerJ. LöbermannM. GötzeT. WeigtJ. LohseA. Von FeldenJ. JordanS. LangeC.M. ZachovalR. MayerleJ. MaieronA. MoradpourD. ChaveJ-P. MorenoC. MucheM. EppleH-J. Müller-SchillingM. KocheiseF. MüllhauptB. PortK. DeterdingK. WedemeyerH. CornbergM. MannsM. ReinhardtL. EllenriederV. RisslandJ. SemelaD. SpenglerU. RockstrohJ. RoebE. SprinzlM. GalleP. StauberR. StremmelW. StreyB. ThimmeR. BoettlerT. TackeF. TeufelA. VogelmannR. EbertM. TomasiewiczK. TrautweinC. KoenenT. WeberT. Wietzke-BraunP. GüntherR. ZizerE. BackhusJ. SeufferleinT. AngeliW. BeckebaumS. DoberauerC. DurmashkinaE. HackelsbergerA. ErhardtA. Garrido-LüneburgA. GattringerH. GennéD. GschwantlerM. GundlingF. HametnerS. SchöflR. HartmannC. HeyerT. HirschiC. JussiosA. KanzlerS. KordeckiN. KrausM. KulligU. WollschlägerS. MagentaL. Terziroli Beretta-PiccoliB. MengesM. MohrL. MuehlenbergK. NiederauC. PaulweberB. PetridesA. PinkernellM. PisoR. RambachW. ReiserM. RieckenB. RiekeA. RothJ. SchellingM. SchleeP. SchneiderA. ScholzD. SchottE. SchuchmannM. Schulten-BaumerU. SeelhoffA. StichA. StickelF. UngemachJ. WalterE. WeberA. WinzerT. AbelsW. AdlerM. AudebertF. BaermannC. BästleinE. BarthR. BarthelK. BeckerW. BehrendsJ. BenningerJ. BergerF. BerzowD. BeyerT. BierbaumM. BlaukatO. BodtländerA. BöhmG. BörnerN. BohrU. BokemeyerB. BruchH.R. BucholzD. BurkhardO. BuschN. ChircaC. DelkerR. DiedrichJ. FrankM. DiehlM. DienethalA. DietelP. DikopoulosN. DreckM. DreherF. DrudeL. EndeK. EhrleU. BaumgartlK. EmkeF. GlosemeyerR. FeltenG. HüppeD. FischerJ. FischerU. FrederkingD. FrickB. FrieseG. GantkeB. GeyerP. SchwindH.R. GlasM. GlaunsingerT. GoebelF. GöbelU. GörlitzB. GrafR. GruberH. HärterG. HerderM. HeuchelT. HeuerS. HöfflK-H. HörsterH. SonneJ-U. HofmannW.P. HolstF. HunstigerM. HurstA. GuedesJ.E. JohnC. JungM. KallinowskiB. KapzanB. KerzelW. KhaykinP. KlarhofM. KlüppelbergU. Wolfratshausen,; Klugewitz, K.; Knapp, B.; Knevels, U.; Kochsiek, T.; Körfer, A.; Köster, A.; Kuhn, M.; Langekamp, A.; Künzig, B.; Link, R.; Littman, M.; Löhr, H.; Lutz, T.; Knecht, G.; Lutz, U.; Mainz, D.; Mahle, I.; Maurer, P.; Mayer, C.; Meister, V.; Möller, H.; Heyne, R.; Moritzen, D.; Mroß, M.; Mundlos, M.; Naumann, U.; Nehls, O.; Ningel, K.R.; Oelmann, A.; Olejnik, H.; Gadow, K.; Pascher, E.; Petersen, J.; Philipp, A.; Pichler, M.; Polzien, F.; Raddant, R.; Riedel, M.; Rietzler, S.; Rössle, M.; Rufle, W.; Rump, A.; Schewe, C.; Hoffmann, C.; Schleehauf, D.; Schmidt, W.; Heinevetter, S.G.; von Fabris, S.J.; Schneider, L.; Schober, A.; Hahn, N.S.; Schwenzer, J.; Seegers, B.; Seidel, T.; Seitel, G.; Sick, C.; Simon, K.; Stähler, D.; Stenschke, F.; Steffens, H.; Stein, K.; Steinmüller, M.; Sternfeld, T.; Strey, B.; Svensson, K.; Tacke, W.; Teuber, G.; Teubner, K.; Thieringer, J.; Tomesch, A.; Trappe, U.; Ullrich, J.; Urban, G.; Usadel, S.; Von Lucadou, A.; Weinberger, F.; Werheid-Dobers, M.; Werner, P.; Winter, T.; Zehnter, E.; Zipf, A. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.J. Hepatol.2023781576610.1016/j.jhep.2022.08.016 36031158
     [Google Scholar]
  27. SarrazinC. Treatment failure with DAA therapy: Importance of resistance.J. Hepatol.20217461472148210.1016/j.jhep.2021.03.004 33716089
     [Google Scholar]
  28. LiD.K. ChungR.T. Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus.Methods Mol. Biol.2019191133210.1007/978‑1‑4939‑8976‑8_1
     [Google Scholar]
  29. MalandrisK. KalopitasG. TheocharidouE. GermanidisG. The role of RASs/RVs in the current management of HCV.Viruses20211310209610.3390/v13102096 34696525
     [Google Scholar]
  30. HarringtonP.R. KomatsuT.E. DemingD.J. DonaldsonE.F. O’RearJ.J. NaegerL.K. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.Hepatology20186762430244810.1002/hep.29693 29194682
     [Google Scholar]
  31. SarrazinC. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.J. Hepatol.201664248650410.1016/j.jhep.2015.09.011 26409317
     [Google Scholar]
  32. ShahidI. IbrahimM.M. NawazM.U. ImamM.T. AlMalkiW.H. Resistance-associated substitutions/variants correlate to therapeutic outcomes of novel direct-acting antivirals in different HCV genotype treated individuals.GenotypingIntechOpen201810.5772/intechopen.76395
     [Google Scholar]
  33. Di StefanoM. IsmailM.H. LeitnerT. FaleoG. Elmnan AdemS.A. ElaminM.O.M.E. EltreifiO. AlwazzehM.J. FioreJ.R. SantantonioT.A. Genetic subtypes and natural resistance mutations in HCV genotype 4 infected Saudi Arabian patients.Viruses2021139183210.3390/v13091832 34578414
     [Google Scholar]
  34. MoherD. LiberatiA. TetzlaffJ. AltmanD.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.Ann. Intern. Med.20091514264269W64.10.7326/0003‑4819‑151‑4‑200908180‑00135 19622511
     [Google Scholar]
  35. LiuT. ZhengX. WangJ. Prediction of protein structural class for low-similarity sequences using support vector machine and PSI-BLAST profile.Biochimie201092101330133410.1016/j.biochi.2010.06.013 20600567
     [Google Scholar]
  36. StoverN.A. CavalcantiA.R. Using NCBI BLAST.Essential Laboratory Techniques.Wiley201710.1002/cpet.8
     [Google Scholar]
  37. QuekJ.P. SerZ. ChewB.L.A. LiX. WangL. SobotaR.M. LuoD. PhooW.W. Dynamic interactions of post cleaved NS2B cofactor and NS3 protease identified by integrative structural approaches.Viruses2022147144010.3390/v14071440 35891424
     [Google Scholar]
  38. JumperJ. EvansR. PritzelA. GreenT. FigurnovM. RonnebergerO. TunyasuvunakoolK. BatesR. ŽídekA. PotapenkoA. BridglandA. MeyerC. KohlS.A.A. BallardA.J. CowieA. ParedesR.B. NikolovS. JainR. AdlerJ. BackT. PetersenS. ReimanD. ClancyE. ZielinskiM. SteineggerM. PacholskaM. BerghammerT. BodensteinS. SilverD. VinyalsO. SeniorA.W. KavukcuogluK. KohliP. HassabisD. Highly accurate protein structure prediction with AlphaFold.Nature2021596787358358910.1038/s41586‑021‑03819‑2 34265844
     [Google Scholar]
  39. WakitaT. PietschmannT. KatoT. DateT. MiyamotoM. ZhaoZ. MurthyK. HabermannA. KräusslichH.G. MizokamiM. BartenschlagerR. LiangT.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.Nat. Med.200511779179610.1038/nm1268 15951748
     [Google Scholar]
  40. ChooQ.L. RichmanK.H. HanJ.H. BergerK. LeeC. DongC. GallegosC. CoitD. SelbyM.R. BarrP.J. Genetic organization and diversity of the hepatitis C virus.Proc. Natl. Acad. Sci.19918862451245510.1073/pnas.88.6.2451 1848704
     [Google Scholar]
  41. ChooQ.L. KuoG. WeinerA.J. OverbyL.R. BradleyD.W. HoughtonM. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.Science1989244490235936210.1126/science.2523562 2523562
     [Google Scholar]
  42. ChevaliezS. PawlotskyJ-M. HCV genome and life cycle.Hepatitis C Viruses: Genomes and Molecular BiologyHorizon Bioscience: Norfolk (UK)2006
     [Google Scholar]
  43. OttoG.A. PuglisiJ.D. The pathway of HCV IRES-mediated translation initiation.Cell2004119336938010.1016/j.cell.2004.09.038 15507208
     [Google Scholar]
  44. Romero-LópezC. Ríos-MarcoP. Berzal-HerranzB. Berzal-HerranzA. The HCV genome domains 5BSL3.1 and 5BSL3.3 act as managers of translation.Sci. Rep.2018811610110.1038/s41598‑018‑34422‑7 30382192
     [Google Scholar]
  45. KimJ.L. MorgensternK.A. LinC. FoxT. DwyerM.D. LandroJ.A. ChambersS.P. MarklandW. LepreC.A. O’MalleyE.T. HarbesonS.L. RiceC.M. MurckoM.A. CaronP.R. ThomsonJ.A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.Cell199687234335510.1016/S0092‑8674(00)81351‑3 8861917
     [Google Scholar]
  46. HorwitzJ.A. DornerM. FrilingT. DonovanB.M. VogtA. LoureiroJ. OhT. RiceC.M. PlossA. Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein.Virology20134391233310.1016/j.virol.2013.01.019 23485372
     [Google Scholar]
  47. ShiryaevS.A. ThomsenE.R. CieplakP. ChudinE. CheltsovA.V. CheeM.S. KozlovI.A. StronginA.Y. New details of HCV NS3/4A proteinase functionality revealed by a high-throughput cleavage assay.PLoS One201274e3575910.1371/journal.pone.0035759 22558217
     [Google Scholar]
  48. LandroJ.A. RaybuckS.A. LuongY.P.C. O’MalleyE.T. HarbesonS.L. MorgensternK.A. RaoG. LivingstonD.J. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: Elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.Biochemistry199736319340934810.1021/bi963054n 9235976
     [Google Scholar]
  49. KimD.W. GwackY. HanJ.H. ChoeJ. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity.Biochem. Biophys. Res. Commun.1995215116016610.1006/bbrc.1995.2447 7575585
     [Google Scholar]
  50. WuJ. BeraA.K. KuhnR.J. SmithJ.L. Structure of the Flavivirus helicase: Implications for catalytic activity, protein interactions, and proteolytic processing.J. Virol.20057916102681027710.1128/JVI.79.16.10268‑10277.2005 16051820
     [Google Scholar]
  51. EggerD. WölkB. GosertR. BianchiL. BlumH.E. MoradpourD. BienzK. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex.J. Virol.200276125974598410.1128/JVI.76.12.5974‑5984.2002 12021330
     [Google Scholar]
  52. MoradpourD. PeninF. Hepatitis C virus proteins: From structure to function.Curr. Top. Microbiol. Immunol.2013369113142
     [Google Scholar]
  53. BlightK.J. KolykhalovA.A. RiceC.M. Efficient initiation of HCV RNA replication in cell culture.Science200029054981972197410.1126/science.290.5498.1972 11110665
     [Google Scholar]
  54. KriegerN. LohmannV. BartenschlagerR. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.J. Virol.200175104614462410.1128/JVI.75.10.4614‑4624.2001 11312331
     [Google Scholar]
  55. AgolV.I. GmylA.P. Emergency services of viral RNAs: Repair and remodeling.Microbiol. Mol. Biol. Rev.2018822e00067e1710.1128/MMBR.00067‑17 29540453
     [Google Scholar]
  56. KumarD. MalikA. AsimM. ChakravartiA. DasR.H. KarP. Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C.World J. Gastroenterol.200814570170810.3748/wjg.14.701 18205258
     [Google Scholar]
  57. ChambersT.J. FanX. DrollD.A. HembradorE. SlaterT. NickellsM.W. DustinL.B. DiBisceglieA.M. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.J. Virol.20057953071308310.1128/JVI.79.5.3071‑3083.2005 15709027
     [Google Scholar]
  58. MadaniT.A. Hepatitis C virus infections reported over 11 years of surveillance in Saudi Arabia.Trans. R. Soc. Trop. Med. Hyg.2009103213213610.1016/j.trstmh.2008.08.001 18789464
     [Google Scholar]
  59. LavanchyD. Evolving epidemiology of hepatitis C virus.Clin. Microbiol. Infect.201117210711510.1111/j.1469‑0691.2010.03432.x 21091831
     [Google Scholar]
  60. Al-FalehF.Z. HuraibS. SbeihF. Al-KarawiM. Al-RashedR. Al-MoflehI.A. SougiyyahM. ShaheenM. RamiaS. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia.J. Viral Hepat.19952629329610.1111/j.1365‑2893.1995.tb00044.x 8732175
     [Google Scholar]
  61. OsobaA.O. Hepatitis C virus genotypes in Saudi Arabia.Saudi Med. J.2002231712 11938356
     [Google Scholar]
  62. FakeehM. ZakiA.M. HepatitisC. Prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia.Am. J. Trop. Med. Hyg.199961688989210.4269/ajtmh.1999.61.889 10674665
     [Google Scholar]
  63. Al TraifI. Al BalwiM.A. AbdulkarimI. HandooF.A. AlqhamdiH.S. AlotaibiM. AljumahA. Al AshqarH.I. BzeiziK. Al QuaizM. AlalwanA. Al HamoudiW. AlswatK. SanaiF. AbdoA. HCV genotypes among 1013 Saudi nationals: A multicenter study.Ann. Saudi Med.2013331101210.5144/0256‑4947.2013.10 23458933
     [Google Scholar]
  64. KhanA. Al BalwiM. AlAyyarL. AlAbdulkareemI. AlbekairyA. AljumahA. Tracing the epidemic history of hepatitis C virus genotypes in Saudi Arabia.Infect. Genet. Evol.201752828810.1016/j.meegid.2017.04.024 28458032
     [Google Scholar]
  65. BosmansJ.L. NouwenE.J. BehetsG. GortemanK. HuraibS.O. ShaheenF.A. MaertensG. VerpootenG.A. ElseviersM.M. de BroeM.E. Prevalence and clinical expression of HCV-genotypes in haemodialysis-patients of two geographically remote countries: Belgium and Saudi-Arabia.Clin. Nephrol.1997474256262 9128793
     [Google Scholar]
  66. QadiA.A. TamimH. AmeenG. Bu-AliA. Al-ArrayedS. FawazN.A. AlmawiW.Y. Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and molecular methods.Am. J. Infect. Control200432849349510.1016/j.ajic.2003.12.009 15573057
     [Google Scholar]
  67. AkbarH.O. Hepatitis C virus infection in Saudi Arabia.Saudi J. Gastroenterol.2004103127131 19861835
     [Google Scholar]
  68. FaragM.M. SofyA.R. MousaA.A. AhmedM.A. AlganzoryM.R. Molecular assay and genotyping of hepatitis C virus among infected Egyptian and Saudi Arabian patients.Virology2015611010.4137/VRT.S32016
     [Google Scholar]
  69. Al ZayedR.M. HamdyN.M. Al-AjlanH.H. ArefN.M. Prevalence of HCV genotypes and viral load in Saudi Arabia.Int. J. Integr. Med2015422641
     [Google Scholar]
  70. AshgarA.H.I. KhanM.Q. AhdalA.M. ThawadiA.S. HelmyA.S. QahtaniA.A. SanaiF.M. Hepatitis C genotype 4: Genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia.Saudi J. Gastroenterol.201319128
     [Google Scholar]
  71. MoneimA.A.S. BamagaM.S. ShehabG.M.G. ElsaadA.A.A.S.A. FarahatF.M. HCV infection among Saudi population: High prevalence of genotype 4 and increased viral clearance rate.PLoS One201271e2978110.1371/journal.pone.0029781 22253780
     [Google Scholar]
  72. ShobokshiO.A. SerebourF.E. SkakniL.I. Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia.Saudi Med. J.200324S2S87S91 12897908
     [Google Scholar]
  73. MohamoudY.A. RiomeS. Abu-RaddadL.J. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence.Int. J. Infect. Dis.20164611612510.1016/j.ijid.2016.03.012 26996460
     [Google Scholar]
  74. ThongV.D. AkkarathamrongsinS. PoovorawanK. TangkijvanichP. PoovorawanY. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication.World J. Gastroenterol.201420112927294010.3748/wjg.v20.i11.2927 24659883
     [Google Scholar]
  75. MarieM.A.M. Genotyping of hepatitis C virus (HCV) in infected patients from Saudi Arabia.Afr. J. Microbiol. Res.201151623882390
     [Google Scholar]
  76. Ghaderi-ZefrehiH. Gholami-FesharakiM. SharafiH. SadeghiF. AlavianS.M. The distribution of hepatitis C virus genotypes in middle eastern countries: A systematic review and meta-analysis.Hepat. Mon.2016169e4035710.5812/hepatmon.40357 27826320
     [Google Scholar]
  77. AbdoA.A. SanaiF.M. Al-FalehF.Z. Epidemiology of viral hepatitis in Saudi Arabia: Are we off the hook?Saudi J. Gastroenterol.2012186349
     [Google Scholar]
  78. HalawaniM.R. Dermatological manifestations of hepatitis C virus infection in Saudi Arabia.Saudi Med. J.2014356531537 24888650
     [Google Scholar]
  79. KoharaT.K. KoharaM. Hepatitis C virus: Viral quasispecies and genotypes.Int. J. Mol. Sci.20171912310.3390/ijms19010023 29271914
     [Google Scholar]
  80. Al-KnawyB. OkamotoH. MekkiA.E.A. KhalafallaE.M. Al WabelA. QaziF. KhanA. ShatoorA. Distribution of hepatitis C genotype and co-infection rate with hepatitis G in Saudi Arabia.Hepatol. Res.2002242959810.1016/S1386‑6346(02)00080‑3 12270737
     [Google Scholar]
  81. HathornE. ElsharkawyA.M. Management of hepatitis C genotype 4 in the directly acting antivirals era.BMJ Open Gastroenterol.201631e00011210.1136/bmjgast‑2016‑000112 27752338
     [Google Scholar]
  82. MannsM.P. McHutchisonJ.G. GordonS.C. RustgiV.K. ShiffmanM. ReindollarR. GoodmanZ.D. KouryK. LingM.H. AlbrechtJ.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial.Lancet2001358928695896510.1016/S0140‑6736(01)06102‑5 11583749
     [Google Scholar]
  83. StraderD.B. WrightT. ThomasD.L. SeeffL.B. Diagnosis, management, and treatment of hepatitis C.Hepatology20043941147117110.1002/hep.20119 15057920
     [Google Scholar]
  84. LebrayP. NalpasB. PichardV.A. BroissandC. SobeskyR. SerpaggiJ. FontaineH. PolS. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.Antivir. Ther.200510676977610.1177/135965350501000605 16218177
     [Google Scholar]
  85. SchaeferM. SchmidtF. FolwacznyC. LorenzR. MartinG. SchindlbeckN. HeldweinW. SoykaM. GrunzeH. KoenigA. LoeschkeK. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.Hepatology200337244345110.1053/jhep.2003.50031 12540795
     [Google Scholar]
  86. ToniuttoP. FabrisC. FumoE. ApollonioL. CaldatoM. AvelliniC. MinisiniR. PirisiM. Pegylated versus standard interferon-α in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.J. Gastroenterol. Hepatol.200520457758210.1111/j.1440‑1746.2005.03795.x 15836706
     [Google Scholar]
  87. AraújoA.R. Peruhype-MagalhãesV. Coelho-dos-ReisJ.G.A. ChavesL.P.V. LimaT.A. PimentelJ.P.D. de PaulaL. AlmeidaC.M. TarragôA.M. TatenoA. LeviJ.E. Teixeira-CarvalhoA. Martins-FilhoO.A. LiraE.F. TorresK.L. TalhariS. MalheiroA. Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C.Immunol. Lett.20131541-2616910.1016/j.imlet.2013.07.010 23973662
     [Google Scholar]
  88. HadziyannisS.J. SetteH.Jr MorganT.R. BalanV. DiagoM. MarcellinP. RamadoriG. BodenheimerH.Jr BernsteinD. RizzettoM. ZeuzemS. PockrosP.J. LinA. AckrillA.M. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose.Ann. Intern. Med.2004140534635510.7326/0003‑4819‑140‑5‑200403020‑00010 14996676
     [Google Scholar]
  89. GeddawyA. IbrahimY.F. ElbahieN.M. IbrahimM.A. Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction.J. Transl. Int. Med.20175181710.1515/jtim‑2017‑0007 28680834
     [Google Scholar]
  90. LokS.F.A. HCV NS5A inhibitors in development.Clin. Liver Dis.201317111112110.1016/j.cld.2012.09.006 23177287
     [Google Scholar]
  91. AsselahT. MarcellinP. SchinaziR.F. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?Liver Int.201838S171310.1111/liv.13673 29427484
     [Google Scholar]
  92. De ClercqE. Current race in the development of DAAs (direct-acting antivirals) against HCV.Biochem. Pharmacol.201489444145210.1016/j.bcp.2014.04.005 24735613
     [Google Scholar]
  93. AsselahT. BoyerN. SaadounD. PeignouxM.M. MarcellinP. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN -free treatment and future perspectives.Liver Int.201636S1475710.1111/liv.13027 26725897
     [Google Scholar]
  94. ChengG. YuM. PengB. LeeY.J. MartinT.A. GongR. BushC. WorthA. NashM. ChanK. YangH. BeranR. TianY. PerryJ. TaylorJ. YangC. PaulsonM. DelaneyW. LinkJ.O. 1191 GS-5816, A second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier.J. Hepatol.201358S1S484S48510.1016/S0168‑8278(13)61192‑7
     [Google Scholar]
  95. CurryM.P. O’LearyJ.G. BzowejN. MuirA.J. KorenblatK.M. FenkelJ.M. ReddyK.R. LawitzE. FlammS.L. SchianoT. TepermanL. FontanaR. SchiffE. FriedM. DoehleB. AnD. McNallyJ. OsinusiA. BrainardD.M. McHutchisonJ.G. BrownR.S.Jr CharltonM. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.N. Engl. J. Med.2015373272618262810.1056/NEJMoa1512614 26569658
     [Google Scholar]
  96. JacobsonI.M. LawitzE. GaneE.J. WillemsB.E. RuaneP.J. NahassR.G. BorgiaS.M. ShafranS.D. WorkowskiK.A. PearlmanB. HylandR.H. StammL.M. SvarovskaiaE. Dvory-SobolH. ZhuY. SubramanianG.M. BrainardD.M. McHutchisonJ.G. BräuN. BergT. AgarwalK. BhandariB.R. DavisM. FeldJ.J. DoreG.J. StedmanC.A.M. ThompsonA.J. AsselahT. RobertsS.K. FosterG.R. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials.Gastroenterology2017153111312210.1053/j.gastro.2017.03.047 28390869
     [Google Scholar]
  97. NgT.I. KrishnanP. Pilot-MatiasT. KatiW. SchnellG. BeyerJ. ReischT. LuL. DekhtyarT. IrvinM. TripathiR. MaringC. RandolphJ.T. WagnerR. CollinsC. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir.Antimicrob. Agents Chemother.2017615e02558e1610.1128/AAC.02558‑16 28193664
     [Google Scholar]
  98. ZeuzemS. FosterG. WangS. 8-or 12-week glecaprevir/pibrentasvir in non-cirrhotic HCV genotype 1 or 3.N. Engl. J. Med.2018378435436910.1056/NEJMoa1702417 29365309
     [Google Scholar]
  99. ZeuzemS. GhalibR. ReddyK.R. PockrosP.J. AriZ.B. ZhaoY. BrownD.D. WanS. DiNubileM.J. NguyenB.Y. RobertsonM.N. WahlJ. BarrE. ButtertonJ.R. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial.Ann. Intern. Med.2015163111310.7326/M15‑0785 25909356
     [Google Scholar]
  100. AndreoneP. ColomboM.G. EnejosaJ.V. KoksalI. FerenciP. MaieronA. MüllhauptB. HorsmansY. WeilandO. ReesinkH.W. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.Gastroenterology.20141472359365e351.
     [Google Scholar]
  101. SchinaziR. HalfonP. MarcellinP. AsselahT. HCV direct-acting antiviral agents: The best interferon-free combinations.Liver Int.201434S1697810.1111/liv.12423 24373081
     [Google Scholar]
  102. SulkowskiM.S. JacobsonI.M. NelsonD.R. Daclatasvir plus sofosbuvir for HCV infection.N. Engl. J. Med.2014370161560156110.1056/NEJMc1401726 24738674
     [Google Scholar]
  103. KishT. AzizA. SorioM. Hepatitis C in a new era: A review of current therapies.P&T2017425316329 28479841
     [Google Scholar]
  104. LenzO. VerbinnenT. LinT.I. VijgenL. CummingsM.D. LindbergJ. BerkeJ.M. DehertoghP. FransenE. ScholliersA. VermeirenK. IvensT. RaboissonP. EdlundM. StormS. VrangL. de KockH. FanningG.C. SimmenK.A. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.Antimicrob. Agents Chemother.20105451878188710.1128/AAC.01452‑09 20176898
     [Google Scholar]
  105. KiefferT.L. De MeyerS. BartelsD.J. SullivanJ.C. ZhangE.Z. TiggesA. DierynckI. SpanksJ. DorrianJ. JiangM. AdiwijayaB. GhysA. BeumontM. KauffmanR.S. AddaN. JacobsonI.M. ShermanK.E. ZeuzemS. KwongA.D. PicchioG. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.PLoS One201274e3437210.1371/journal.pone.0034372 22511937
     [Google Scholar]
  106. AguiarB.F. CamposG.R.F. RodriguesJ.P.V. MarquesN.N. MolinaB.F. BittarC. SouzaF.F. MartinelliA.L.C. RahalP. PereiraL.R.L. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.Clin. Res. Hepatol. Gastroenterol.202044332933910.1016/j.clinre.2019.07.015 31523019
     [Google Scholar]
  107. GaoM. NettlesR.E. BelemaM. SnyderL.B. NguyenV.N. FridellR.A. Serrano-WuM.H. LangleyD.R. SunJ.H. O’BoyleD.R.II LemmJ.A. WangC. KnipeJ.O. ChienC. ColonnoR.J. GraselaD.M. MeanwellN.A. HamannL.G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Nature201046572949610010.1038/nature08960 20410884
     [Google Scholar]
  108. FridellR.A. QiuD. WangC. ValeraL. GaoM. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Antimicrob. Agents Chemother.20105493641365010.1128/AAC.00556‑10 20585111
     [Google Scholar]
  109. CostaV.D. DelvauxN. MelloB.C.E. NunesE.P. de SousaP.S.F. de RodriguesS.L.L.L.X. LampeE. do MelloA.F.C. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.Clin. Res. Hepatol. Gastroenterol.201943670070610.1016/j.clinre.2019.02.009 30880098
     [Google Scholar]
  110. FlintM. MullenS. DeatlyA.M. ChenW. MillerL.Z. RalstonR. BroomC. EminiE.A. HoweA.Y.M. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).Antimicrob. Agents Chemother.200953240141110.1128/AAC.01081‑08 18936191
     [Google Scholar]
  111. SoumanaD.I. AliA. SchifferC.A. Structural analysis of asunaprevir resistance in HCV NS3/4A protease.ACS Chem. Biol.20149112485249010.1021/cb5006118 25243902
     [Google Scholar]
  112. McPheeF. FriborgJ. LevineS. ChenC. FalkP. YuF. HernandezD. LeeM.S. ChaniewskiS. SheafferA.K. PasquinelliC. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.Antimicrob. Agents Chemother.20125673670368110.1128/AAC.00308‑12 22508297
     [Google Scholar]
  113. TongX. ChaseR. SkeltonA. ChenT. WrightminogueJ. MalcolmB. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.Antiviral Res.2006702283810.1016/j.antiviral.2005.12.003 16448708
     [Google Scholar]
  114. WalkerA. FilkeS. LübkeN. ObermeierM. KaiserR. HäussingerD. TimmJ. BockH.H. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure.Virol. J.201714110610.1186/s12985‑017‑0779‑4 28595606
     [Google Scholar]
  115. ValletS. VironF. HenquellC. Le GuillemetteG.H. LagathuG. AbravanelF. TrimouletP. SoussanP. SchvoererE. RosenbergA. GouriouS. ColsonP. IzopetJ. PayanC. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.Antivir. Ther.20111671093110210.3851/IMP1900 22024525
     [Google Scholar]
  116. MorsicaG. AndolinaA. MerliM. MessinaE. HassonH. LazzarinA. FoppaU.C. BagaglioS. NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.Arch. Virol.201716282271227710.1007/s00705‑017‑3341‑1 28421367
     [Google Scholar]
  117. PaolucciS. FiorinaL. MarianiB. GulminettiR. NovatiS. BarbariniG. BrunoR. BaldantiF. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Virol. J.201310135510.1186/1743‑422X‑10‑355 24341898
     [Google Scholar]
  118. MartínezA.P. CulassoA.C.A. PérezP.S. RomanoV. CamposR.H. RidruejoE. GarcíaG. Di LelloF.A. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.Virus Res.201724014014610.1016/j.virusres.2017.08.006 28837817
     [Google Scholar]
  119. SarrazinC. SobolD.H. SvarovskaiaE.S. DoehleB.P. PangP.S. ChuangS.M. MaJ. DingX. AfdhalN.H. KowdleyK.V. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir.Gastroenterology.20161513501512e501
     [Google Scholar]
  120. AriasA. AguileraA. SorianoV. GutiérrezB.L. LledóG. NavarroD. TreviñoA. OteroE. PeñaJ.M. MonsC.V. de MendozaC. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.Antivir. Ther.201722430731210.3851/IMP3061 27341294
     [Google Scholar]
  121. MichalukZ.D. JaroszewiczJ. BuczyńskaI. SimonK. LorencB. ZdunekT.M. TomasiewiczK. SitkoM. GarlickiA. JanczewskaE. DybowskaD. HalotaW. PawłowskaM. PabjanP. MazurW. AndrzejukC.A. BerakH. HorbanA. SochaŁ. KlapaczyńskiJ. PiekarskaA. BlaszkowskaM. WdowikB.T. DobrackaB. TroninaO. DerońZ. WarzechaB.J. LauransŁ. FlisiakR. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4.J. Gastroenterol. Hepatol.20203571238124610.1111/jgh.14936 31734959
     [Google Scholar]
  122. El-KhayatH. FouadY. MohamedH.I. El-AminH. KamalE.M. MaherM. RiskA. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.Aliment. Pharmacol. Ther.201847567467910.1111/apt.14482 29314146
     [Google Scholar]
  123. AhmedO.A. ElsebaeyM.A. FouadM.H.A. ElashryH. ElshafieA.I. ElhadidyA.A. EshebaN.E. ElnaggarM.H. SolimanS. Abd-ElsalamS. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.Infect. Drug Resist.20181144144510.2147/IDR.S160593 29628768
     [Google Scholar]
  124. De FrancescoM.A. GargiuloF. ZaltronS. SpinettiA. CastelliF. CarusoA. DAA treatment failure in a HIV/HBV/HCV co-infected patient carrying a chimeric HCV genotype 4/1b.Int. J. Environ. Res. Public Health202219181165510.3390/ijerph191811655 36141921
     [Google Scholar]
  125. FouratiS. RodriguezC. HézodeC. SoulierA. RuizI. PoiteauL. ChevaliezS. PawlotskyJ.M. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.Hepatology201969251352310.1002/hep.30225 30125371
     [Google Scholar]
  126. FerenciP. Treatment of hepatitis C in difficult-to-treat patients.Nat. Rev. Gastroenterol. Hepatol.201512528429210.1038/nrgastro.2015.53 25895822
     [Google Scholar]
  127. SarrazinC. CooperC.L. MannsM.P. ReddyK.R. KowdleyK.V. RobertsS.K. Dvory-SobolH. SvarovskiaE. MartinR. CamusG. DoehleB.P. StammL.M. HylandR.H. BrainardD.M. MoH. GordonS.C. BourliereM. ZeuzemS. FlammS.L. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.J. Hepatol.20186961221123010.1016/j.jhep.2018.07.023 30098373
     [Google Scholar]
  128. NejabatN. HosseiniS.Y. SarvariJ. GorzinA.A. FattahiM.R. RasoolianM. The investigation of drug resistance substitutions in NS3 protease sequence of hepatitis C virus from non-responder patients.Asian Pac. J. Cancer Prev.20192082311231710.31557/APJCP.2019.20.8.2311 31450900
     [Google Scholar]
  129. ZeuzemS. MizokamiM. PiankoS. MangiaA. HanK.H. MartinR. SvarovskaiaE. Dvory-SobolH. DoehleB. HedskogC. YunC. BrainardD.M. KnoxS. McHutchisonJ.G. MillerM.D. MoH. ChuangW.L. JacobsonI. DoreG.J. SulkowskiM. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.J. Hepatol.201766591091810.1016/j.jhep.2017.01.007 28108232
     [Google Scholar]
  130. BertoliA. SorboM.C. AragriM. LenciI. TetiE. PolilliE. Di MaioV.C. GianserraL. BiliottiE. MasettiC. MagniC.F. BabudieriS. NicoliniL.A. MilanaM. CacciatoreP. SarmatiL. PellicelliA. PaolucciS. CraxìA. MoriscoF. PalittiV.P. SicilianoM. CoppolaN. IapadreN. PuotiM. RizzardiniG. TalianiG. PasquazziC. AndreoniM. ParrutiG. AngelicoM. PernoC.F. CentoV. SilbersteinC.F. AndreoneP. BaldantiF. BarbariniG. BoccaccioV. BoglioneL. BolisM. BonoraS. BorghiV. BrancaccioG. BrunoS. BruzzoneB. CalvarusoV. CaporasoN. CiaccioA. CiancioA. ColombattoP. CozzolongoR. D’AmbrosioC. D’EttorreG. De LeonardisF. De LucaA. Di BiagioA. Di PerriG. FranciosoS. GaetaG.B. GasbarriniA. GhisettiV. GiorginiA. GriecoA. GubertiniG. GulminettiR. LambiaseL. LandonioS. LichtnerM. MaidaI. MarencoS. MarinaroL. MaseratiR. MelisM. MenzaghiB. MeregalliE. MicheliV. NieroF. PaoloniM. PieriA. RendinaM. RomagnoliD. RossettiB. RuggieroT. SangiovanniV. StaraceM. SticchiL. TarquiniP. ToniuttoP. VulloV. ZazziM. Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1–4 in Italy.Sci. Rep.201881898810.1038/s41598‑018‑26862‑y 29895871
     [Google Scholar]
  131. WeiL. OmataM. LimY.S. XieQ. HouJ.L. JiaJ. HedskogC. MartinR. DoehleB. YangJ. De-OertelS. MassettoB. KerseyK. BrainardD.M. SvarovskaiaE. MoH. HanK.H. MizokamiM. DuanZ. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.Antiviral Res.201815817818410.1016/j.antiviral.2018.08.001 30120954
     [Google Scholar]
  132. JiangM. ManiN. LinC. ArdzinskiA. NelsonM. ReaganD. BartelsD. ZhouY. NicolasO. RaoB.G. MühU. HanzelkaB. TiggesA. RijnbrandR. KiefferT.L. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.Antimicrob. Agents Chemother.201357126236624510.1128/AAC.01578‑13 24100495
     [Google Scholar]
  133. AnagnostouO. ManolakopoulosS. BakoyannisG. PapatheodoridisG. ZisouliA. GigiR.M. ManesisE. KetikoglouI. DalekosG. GogosC. VassiliadisT. TzourmakliotisD. KaratapanisS. KanatakisS. Zoumpoulis; Hounta, A.; Koutsounas, S.; Giannoulis, G.; Tassopoulos, N.; Touloumi, G. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a greek nationwide cohort study.Hippokratia20141815764 25125954
     [Google Scholar]
  134. BrzdękM. DobrowolskaK. FlisiakR. Zarębska-MichalukD. Genotype 4 hepatitis C virus-a review of a diverse genotype.Adv. Med. Sci.2023681545910.1016/j.advms.2022.12.003 36640687
     [Google Scholar]
  135. SchnellG. TripathiR. BeyerJ. ReischT. KrishnanP. LuL. DekhtyarT. HallC. VilchezR.A. Pilot-MatiasT. CollinsC. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.Antimicrob. Agents Chemother.201559116807681510.1128/AAC.01229‑15 26282418
     [Google Scholar]
  136. ManiN. Clinically relevant HCVdrug resistance mutations figure and tables.Ann Forum Collab HIV Res.2012142110
     [Google Scholar]
  137. WylesD.L. LuetkemeyerA.F. Understanding hepatitis C virus drug resistance: Clinical implications for current and future regimens.Top. Antivir. Med.2017253103109 28820725
     [Google Scholar]
  138. RahimiP. SharafiH. BahramaliG. SajadianFard, F.; Asadi, N.S.; Alavian, S.M.; Mobarakeh, I.V.; Moravej, S.Z. Prevalence of naturally-occurring NS5A and NS5B resistance-associated substitutions in Iranian patients with chronic hepatitis C infection.Front. Microbiol.20211161737510.3389/fmicb.2020.617375 33584581
     [Google Scholar]
  139. LaferrièreM.V. DieterichD.T. GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV.Future Virol.20127653754610.2217/fvl.12.34
     [Google Scholar]
  140. SayanM. YıldırımF.S. AkhanS. YıldırımA.A. ŞirinG. CabalakM. DemirM. CanS. ErsözG. AltıntaşE. EnsaroğluF. AkbulutA. ŞenerA. DeveciA. NS5A resistance – associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey.Int. J. Infect. Dis.202095848910.1016/j.ijid.2020.03.061 32302766
     [Google Scholar]
  141. MushtaqS. HashmiA.H. KhanA. KazmiA.R.S.M. ManzoorS. Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals.Front. Pharmacol.20221389446010.3389/fphar.2022.894460 35571102
     [Google Scholar]
  142. AtifM. MustaanM.A. FalakS. GhaffarA. MunirB. Targeting the effect of sofosbuvir on selective oncogenes expression level of hepatocellular carcinoma Ras/Raf/MEK/ERK pathway in Huh7 cell line.Saudi J. Biol. Sci.202229810333210.1016/j.sjbs.2022.103332 35813116
     [Google Scholar]
  143. MarascioN. PaviaG. StrazzullaA. DierckxT. CuypersL. VranckenB. BarrecaG. MiranteT. MalangaD. OliveiraD. VandammeA.M. TortiC. LibertoM. FocàA. Detection of natural resistance-associated substitutions by ion semiconductor technology in HCV1b positive, direct-acting antiviral agents-naïve patients.Int. J. Mol. Sci.2016179141610.3390/ijms17091416 27618896
     [Google Scholar]
  144. LinC. LinK. LuongY.P. RaoB.G. WeiY.Y. BrennanD.L. FulghumJ.R. HsiaoH.M. MaS. MaxwellJ.P. CottrellK.M. PerniR.B. GatesC.A. KwongA.D. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms.J. Biol. Chem.200427917175081751410.1074/jbc.M313020200 14766754
     [Google Scholar]
/content/journals/npj/10.2174/0122103155291056240327033157
Loading
A Systematic Review on the Evolution of Natural Mutation-dependent Antiviral Drug Resistance in Hepatitis C Virus (HCV) Genotypes Prevalent in Saudi Arabia: A Genomic and Therapeutic Perspective
Natural Products Journal, The 15, E030424228571 (2025); https://doi.org/10.2174/0122103155291056240327033157
/content/journals/npj/10.2174/0122103155291056240327033157
/content/journals/npj/10.2174/0122103155291056240327033157
Loading

Data & Media loading...

Supplements

PRISMA checklist is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): DAA; genotypes; HCV; mutations; NS3; NS5A; NS5B; ORF; RAAS

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test